Even more challenging, controversial data suggest that cannabinoid agonists may foster tumorigenesis in some entities: For an acute myeloid leukemia model it has been demonstrated that CB2 has oncogene properties abrogating myeloid differentiation [13, 20]. This evidence concerns the gene CNR2 and acute myeloid leukemia.